TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27542789

Group type: EXPERIMENTAL
Intervention: 23 mm Lotus valve
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 25 mm Lotus valve
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 27 mm Lotus valve
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Transfemoral TAVI with the repositionable Lotus valve
Number of subjects: 110
Study: 27542843

Group type: EXPERIMENTAL
Intervention: COPD-6™ lung function testing
Number of subjects: 227
Study: 27543317

Group type: EXPERIMENTAL
Intervention: SB-related text messages
Number of subjects: 82

Group type: COMPARATOR
Intervention: Text messages unrelated to SB
Number of subjects: 82
Study: 27543526

Group type: EXPERIMENTAL
Intervention: Non-invasive beat-to-beat Nexfin finger BP (BPfin)
Number of subjects: 25
Study: 27543531

Group type: EXPERIMENTAL
Intervention: High SPOC scores (>80)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Intermediate SPOC scores (41-80)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Low SPOC scores (≤40)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Addition of SPOC scores to regression model
Number of subjects: 267
Study: 27543601

Group type: EXPERIMENTAL
Intervention: FGFR2-ADC (BAY 1187982)
Number of subjects: 0
Study: 27543800

Group type: EXPERIMENTAL
Intervention: Intravascular imaging (used in 38% of cases)
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (36% of imaging cases)
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (3% of imaging cases)
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Both imaging modalities (1.45% of imaging cases)
Number of subjects: 619
Study: 27544054

Group type: EXPERIMENTAL
Intervention: PRAME immunotherapeutic (20 μg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PRAME immunotherapeutic (100 μg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PRAME immunotherapeutic (500 μg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PRAME immunotherapeutic (all doses)
Number of subjects: 60
Study: 27544283

Group type: EXPERIMENTAL
Intervention: NOURISH+ intervention
Number of subjects: 0
Study: 27544327

Group type: EXPERIMENTAL
Intervention: Group 1 (without lacquer cracks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Group 2 (with lacquer cracks)
Number of subjects: 32
Study: 27544377

Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 27544832

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea indices
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Daily energy expenditure (DEE)
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Osteopenia (OP) prevalence
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Osteoporosis (OS) prevalence
Number of subjects: 461
Study: 27545672

Group type: EXPERIMENTAL
Intervention: Screen time behaviour
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Energy intake
Number of subjects: 0
Study: 27546069

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 195
Study: 27547173

Group type: EXPERIMENTAL
Intervention: Standard and contingency management treatment
Number of subjects: 81
Study: 27547422

Group type: COMPARATOR
Intervention: Short-term intensive insulin therapy (IIT) for 2-4 weeks (basal detemir, bolus aspart) followed by placebo therapy for 48 weeks
Number of subjects: 25
Study: 27547431

Group type: EXPERIMENTAL
Intervention: Recruitment of older patients to the ICON-1 study
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Comparison of age between those able to consent and those unable to consent
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Gender differences in participation
Number of subjects: 300
Study: 27547429

Group type: EXPERIMENTAL
Intervention: BQ-123 (selective endothelin A receptor antagonist)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 27548475

Group type: EXPERIMENTAL
Intervention: Galectin-3 concentration in subjects with delayed enhancement (DE)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Galectin-3 concentration in subjects without delayed enhancement (DE)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Correlation between myocardial fibrosis and Gal-3 concentration
Number of subjects: 61
Study: 27548863

Group type: EXPERIMENTAL
Intervention: Sensory avoiding behaviors
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Sensory seeking behaviors
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 77
Study: 27549244

Group type: EXPERIMENTAL
Intervention: FibroTest for fibrosis staging
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: ActiTest for inflammation activity grading
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: SteatoTest for steatosis grading
Number of subjects: 600
Study: 27549584

Group type: EXPERIMENTAL
Intervention: Standardized low-sodium diet
Number of subjects: 25

Group type: COMPARATOR
Intervention: Ad libitum sodium intake (Control)
Number of subjects: 25
Study: 27550351

Group type: EXPERIMENTAL
Intervention: Ceftolozane-tazobactam 3 g every 8 hours (q8h)
Number of subjects: 20
Study: 27550526

Group type: EXPERIMENTAL
Intervention: Complete en bloc omentectomy and modified D2 lymphadenectomy
Number of subjects: 100
Study: 27551051

Group type: EXPERIMENTAL
Intervention: Endocrine treatment
Number of subjects: 111
Study: 27551171

Group type: EXPERIMENTAL
Intervention: Acetaminophen plus 10 mg/day of native type II collagen (group AC+CII)
Number of subjects: 39

Group type: COMPARATOR
Intervention: 1500 mg/day of acetaminophen (group AC)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Comparison between AC+CII and AC groups
Number of subjects: 39

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 39
Study: 27551314

Group type: EXPERIMENTAL
Intervention: 30% caloric restriction (CR) diet for 3 weeks after a 2-week weight maintenance diet
Number of subjects: 19
Study: 27551317

Group type: COMPARATOR
Intervention: Oxidized fish oil (8 g daily, EPA+DHA 1.6 g)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: High-quality fish oil (8 g daily, EPA+DHA 1.6 g)
Number of subjects: 35
Study: 27551569

Group type: EXPERIMENTAL
Intervention: Implementation of an institutional registry of elderly patients with hip fracture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up at 3 and 12 months postfracture
Number of subjects: 0
Study: 27551690

Group type: EXPERIMENTAL
Intervention: DPP-based lifestyle intervention for 12 months
Number of subjects: 223

Group type: COMPARATOR
Intervention: Delayed-start group (6-month delayed intervention)
Number of subjects: 223
Study: 27551814

Group type: EXPERIMENTAL
Intervention: Ultrashort echo-time MRI
Number of subjects: 11

Group type: COMPARATOR
Intervention: Computed tomography (CT)
Number of subjects: 11
Study: 27551991

Group type: EXPERIMENTAL
Intervention: BDNF minor allele
Number of subjects: 3180

Group type: EXPERIMENTAL
Intervention: MC4R rs571312
Number of subjects: 3180

Group type: EXPERIMENTAL
Intervention: BDNF rs2030323 (non-Hispanic white participants)
Number of subjects: 3180

Group type: EXPERIMENTAL
Intervention: FTO rs1421085 (non-Hispanic white participants)
Number of subjects: 3180
Study: 27552578

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonist (VKA) treatment in Asia (1356 patients, 37.8%)
Number of subjects: 16162

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonist (VKA) treatment in ORW (7081 patients, 53.3%)
Number of subjects: 16162
Study: 27552827

Group type: EXPERIMENTAL
Intervention: Multimodal MRI techniques including structure magnetic resonance imaging (sMRI), resting state functional magnetic resonance imaging (rs-fMRI), diffusion kurtosis imaging (DKI), and three-dimensional pseudo-continuous arterial spin labeling (3D-pCASL)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 159
Study: 27552976

Group type: EXPERIMENTAL
Intervention: Natalizumab (Tysabri®)
Number of subjects: 355
Study: 27553184

Group type: EXPERIMENTAL
Intervention: Ablation using plasma energy
Number of subjects: 104

Group type: COMPARATOR
Intervention: Cystectomy
Number of subjects: 104
Study: 27553492

Group type: EXPERIMENTAL
Intervention: Personalised web-based physiotherapy programme
Number of subjects: 50
Study: 27554014

Group type: EXPERIMENTAL
Intervention: LNG IUS (levonorgestrel intrauterine system) 52 mg inserted at 2 weeks postpartum
Number of subjects: 50
Study: 27554105

Group type: EXPERIMENTAL
Intervention: Contemporary treatment (pharmacological and invasive)
Number of subjects: 0
Study: 27555917

Group type: EXPERIMENTAL
Intervention: Exergaming using XBOX Kinect™
Number of subjects: 50

Group type: COMPARATOR
Intervention: Traditional gym-based exercise (TGB)
Number of subjects: 50
Study: 27556153

Group type: EXPERIMENTAL
Intervention: Active tube clearance (ATC)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Conventional chest tube drainage
Number of subjects: 252
Study: 27556234

Group type: EXPERIMENTAL
Intervention: SARP-3 cohort with exacerbation prone patients (≥3 exacerbations)
Number of subjects: 709
Study: 27556389

Group type: EXPERIMENTAL
Intervention: Ear Acupuncture (EA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (detuned ultrasound)
Number of subjects: 80
Study: 27556408

Group type: EXPERIMENTAL
Intervention: Acute exacerbations of COPD
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Acute respiratory events in smokers without COPD
Number of subjects: 2000
Study: 27557531

Group type: EXPERIMENTAL
Intervention: Psychological distress measured by the 4-item Patient Health Questionnaire (PHQ-4)
Number of subjects: 1575

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 1575

Group type: EXPERIMENTAL
Intervention: Comorbid psychiatric disorder
Number of subjects: 1575

Group type: EXPERIMENTAL
Intervention: Discharge to a post-acute care institution
Number of subjects: 1575

Group type: EXPERIMENTAL
Intervention: Unplanned rehospitalisation
Number of subjects: 1575

Group type: EXPERIMENTAL
Intervention: Unplanned visit at general practitioner
Number of subjects: 1575
Study: 27557643

Group type: EXPERIMENTAL
Intervention: Selinexor combined with pegylated liposomal doxorubicin (PLD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selinexor combined with doxorubicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selinexor/doxorubicin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: TOP2A knockdown
Number of subjects: 0
Study: 27557655

Group type: EXPERIMENTAL
Intervention: Highest quintile of total red meat consumption
Number of subjects: 74645
Study: 27557657

Group type: EXPERIMENTAL
Intervention: Weight and fat loss intervention over 6 months
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Weight and fat loss intervention in iron-deficient subjects (n = 17)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Weight and fat loss intervention in iron-sufficient subjects (n = 21)
Number of subjects: 43
Study: 27557801

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention program (VEND-RISK)
Number of subjects: 26
Study: 27557949

Group type: EXPERIMENTAL
Intervention: Antipsychotic-related dopamine D2/3 receptor occupancy
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Antipsychotic medications
Number of subjects: 41
Study: 27558140

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) exceeding 2 METs
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) exceeding 3 METs
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Sedentary Time (ST)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: All PA categories (including Light PA, Moderate PA, Vigorous PA)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Vigorous Physical Activity (VPA)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Physical Activity Energy Expenditure (PAEE), Moderate PA (MPA), Vigorous PA (VPA)
Number of subjects: 410
Study: 27558181

Group type: EXPERIMENTAL
Intervention: Rifamycin treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C. difficile isolates characterization
Number of subjects: 0
Study: 27558463

Group type: EXPERIMENTAL
Intervention: Tibiopedal access
Number of subjects: 197
Study: 27558527

Group type: COMPARATOR
Intervention: Children with at least one piece of bedroom electronic media
Number of subjects: 5859

Group type: EXPERIMENTAL
Intervention: More frequent physical activity in the home and yard
Number of subjects: 5859

Group type: EXPERIMENTAL
Intervention: Ownership of more frequently used play equipment
Number of subjects: 5859

Group type: EXPERIMENTAL
Intervention: Higher social support for physical activity
Number of subjects: 5859

Group type: EXPERIMENTAL
Intervention: Play equipment ownership
Number of subjects: 5859
Study: 27558635

Group type: EXPERIMENTAL
Intervention: 1 × 10^6 CEA-pulsed DCs mixed with tetanus toxoid (adjuvant) and low-dose interleukin-2 administered subcutaneously after final DC vaccination.
Number of subjects: 12
Study: 27560141

Group type: EXPERIMENTAL
Intervention: Family-based childhood obesity treatment program
Number of subjects: 1125
Study: 27561160

Group type: EXPERIMENTAL
Intervention: Prostar XL
Number of subjects: 585

Group type: COMPARATOR
Intervention: ProGlide
Number of subjects: 585
Study: 27561167

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy in PEGASUS-like population (Group 1)
Number of subjects: 2490

Group type: COMPARATOR
Intervention: Control group (Group 2, patients with ≥1 exclusion criterion for the trial)
Number of subjects: 2490

Group type: COMPARATOR
Intervention: Control group (Group 3, patients meeting neither inclusion nor exclusion criteria)
Number of subjects: 2490

Group type: EXPERIMENTAL
Intervention: Age as a risk factor in PEGASUS-like patients
Number of subjects: 2490
Study: 27561198

Group type: EXPERIMENTAL
Intervention: Pegylated interferon plus ribavirin therapy
Number of subjects: 156
Study: 27561197

Group type: EXPERIMENTAL
Intervention: NYHA class I
Number of subjects: 847

Group type: EXPERIMENTAL
Intervention: NYHA class II
Number of subjects: 847

Group type: EXPERIMENTAL
Intervention: NYHA class III
Number of subjects: 847

Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 847

Group type: COMPARATOR
Intervention: Incidence of appropriate ICD intervention
Number of subjects: 847

Group type: COMPARATOR
Intervention: Incidence of ICD-unresponsive sudden death
Number of subjects: 847
Study: 27561272

Group type: EXPERIMENTAL
Intervention: MK-8150, single doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MK-8150, multiple doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MK-8150, 28-day studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MK-8150, preclinical studies in telemetered dogs
Number of subjects: 0
Study: 27561720

Group type: EXPERIMENTAL
Intervention: Clofarabine (30 mg/m²) and cytosine arabinoside followed by reduced-intensity conditioning before allogeneic stem-cell transplantation
Number of subjects: 24
Study: 27561722

Group type: EXPERIMENTAL
Intervention: Ph-like ALL patients (n=19)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Remaining BCP-ALL patients (n=40)
Number of subjects: 207
Study: 27561844

Group type: EXPERIMENTAL
Intervention: DEBIRI (drug eluting PVA microspheres loaded with irinotecan)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: DEBIRI (median dose of 103 mg irinotecan)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: DEBIRI
Number of subjects: 40
Study: 27562475

Group type: COMPARATOR
Intervention: Long-term CRC survivors
Number of subjects: 708
Study: 27562938

Group type: EXPERIMENTAL
Intervention: Transoral endoscopic gastroplasty using a simple triangulation platform and a dedicated suturing device
Number of subjects: 11
Study: 27564386

Group type: EXPERIMENTAL
Intervention: Vaginal bowel control system
Number of subjects: 110
Study: 27565186

Group type: EXPERIMENTAL
Intervention: Wearable sensors (smartwatch, smartphone, fall detector) used continuously for 3 months with a customized smartphone app (Fox Insight)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Wearable sensors (smartwatch, smartphone, fall detector)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Self-reported medication intake and fall incidents via smartphone app
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Data collected from wearable sensors
Number of subjects: 1000
Study: 27565882

Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir for 8 weeks
Number of subjects: 2099

Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir for 12 weeks
Number of subjects: 2099

Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir for 24 weeks
Number of subjects: 2099

Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir plus ribavirin for 12 weeks
Number of subjects: 2099

Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir plus ribavirin for 24 weeks
Number of subjects: 2099
Study: 27565932

Group type: EXPERIMENTAL
Intervention: ASP3026 at a dose of 125mg once daily
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: LDK378 (ceritinib) at a dose of 750mg once daily
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Serum hyaluronan levels monitoring
Number of subjects: 1
Study: 27566109

Group type: EXPERIMENTAL
Intervention: >20-43% IRS protection
Number of subjects: 289

Group type: COMPARATOR
Intervention: >0-20% IRS protection
Number of subjects: 289

Group type: COMPARATOR
Intervention: No IRS protection
Number of subjects: 289
Study: 27566701

Group type: EXPERIMENTAL
Intervention: LY3022856 at doses of 5-30 mg/kg weekly (qwk)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: LY3022856 at 30 mg/kg qwk in colorectal cancer patients
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: LY3022856
Number of subjects: 44
Study: 27566720

Group type: EXPERIMENTAL
Intervention: 2D longitudinal strain (2DLS) analysis
Number of subjects: 605

Group type: COMPARATOR
Intervention: Control group (patients without ACS)
Number of subjects: 605
Study: 27566836

Group type: EXPERIMENTAL
Intervention: Postnatal stress
Number of subjects: 473

Group type: COMPARATOR
Intervention: Pre- and perinatal stress
Number of subjects: 473
Study: 27567280

Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 0
Study: 27567500

Group type: EXPERIMENTAL
Intervention: Rifampin 20 mg/kg/day
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Rifampin 15 mg/kg/day
Number of subjects: 180

Group type: COMPARATOR
Intervention: Rifampin 10 mg/kg/day (control)
Number of subjects: 180
Study: 27567680

Group type: EXPERIMENTAL
Intervention: Face transplantation
Number of subjects: 20
Study: 27568125

Group type: EXPERIMENTAL
Intervention: RAMP-DM
Number of subjects: 29870

Group type: COMPARATOR
Intervention: Control (usual primary care)
Number of subjects: 29870
Study: 27568453

Group type: EXPERIMENTAL
Intervention: Anti-dementia drugs (acetylcholinesterase inhibitors and memantine)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control (patients with dementia who did not take anti-dementia drugs)
Number of subjects: 112
Study: 27568864

Group type: EXPERIMENTAL
Intervention: Eculizumab treatment
Number of subjects: 4
Study: 27570087

Group type: EXPERIMENTAL
Intervention: Ofatumumab consolidation (1000 mg once every 4 weeks)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Ofatumumab induction (300 mg on day 1 and 1000 mg on day 2; cycles 2-6: 1000 mg on day 1)
Number of subjects: 34
Study: 27570245

Group type: EXPERIMENTAL
Intervention: Delafloxacin 300 mg intravenous
Number of subjects: 3

Group type: COMPARATOR
Intervention: Matched healthy controls
Number of subjects: 3
Study: 27570627

Group type: EXPERIMENTAL
Intervention: In-home telerehabilitation (TELE group)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Face-to-face rehabilitation (CLINIC group)
Number of subjects: 52
Study: 27570807

Group type: EXPERIMENTAL
Intervention: IL-6 c.-174 CC genotype
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-6 genotypes
Number of subjects: 0
Study: 27571185

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 99
Study: 27572392

Group type: EXPERIMENTAL
Intervention: Meropenem 2 g every 8 hours (q8h)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Meropenem 1 g every 8 hours (q8h)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Meropenem 1 g every 6 hours (q6h)
Number of subjects: 82
Study: 27573206

Group type: EXPERIMENTAL
Intervention: Andexanet alfa (bolus followed by a 2-hour infusion)
Number of subjects: 67
Study: 27573260

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 0
Study: 27573636

Group type: EXPERIMENTAL
Intervention: Group teleconferences after interim analyses
Number of subjects: 1741
Study: 27573653

Group type: EXPERIMENTAL
Intervention: Trastuzumab therapy (only group 1 showed significant benefit)
Number of subjects: 10468

Group type: COMPARATOR
Intervention: Group 4 (not associated with significantly worse DFS or OS)
Number of subjects: 10468

Group type: COMPARATOR
Intervention: Group 2 (no significant benefit from trastuzumab therapy)
Number of subjects: 10468
Study: 27573663

Group type: EXPERIMENTAL
Intervention: Vinblastine (6 mg/m2) administered once per week
Number of subjects: 0
Study: 27573937

Group type: EXPERIMENTAL
Intervention: Roux-en-Y Gastric Bypass (RYGB)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Laparoscopic Adjustable Gastric Banding (LAGB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Very Low Caloric Intake (VLCI)
Number of subjects: 20
Study: 27574516

Group type: EXPERIMENTAL
Intervention: Combinatorial weight-adjusted disability score (CombiWISE)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: CombiWISE
Number of subjects: 58
Study: 27574837

Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone treatment (NCT00634803)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Opioid treatment program-based methadone maintenance treatment (NCT00727675)
Number of subjects: 170
Study: 27575787

Group type: EXPERIMENTAL
Intervention: Separable cluster electrode
Number of subjects: 79

Group type: COMPARATOR
Intervention: Multiple internally-cooled electrodes
Number of subjects: 79
Study: 27575911

Group type: EXPERIMENTAL
Intervention: Lung Clearance Index (LCI)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Lung Clearance Index (LCI) and Magnetic Resonance Imaging (MRI)
Number of subjects: 97